Abstract 297P
Background
Acute radiation dermatitis is a prevalent adverse effect of radiotherapy in patients with breast cancer, and there is a lack of high-quality data regarding its prevention and management, which leads to a lack of standardized care This study employs a modified Delphi process to compile the perspectives of Canadian breast cancer radiation oncology and dermatology experts, aiming to establish consensus-based recommendations for the prevention and management of acute radiation dermatitis in breast cancer patients.
Methods
A four-round modified Delphi consensus process was organised with the participation of 19 Canadian experts. The process involved a systematic review of existing literature on the prevention and treatment of acute radiation dermatitis in breast cancer, from January 1946 to July 2023. Participants then provided their opinions on the strength and quality of the evidence for the 59 identified interventions. A second round involved assessing the degree to which the intervention would be recommended in either low- or high-risk settings. Two other rounds were used to consolidate consensus, which was determined by achieving a minimum agreement threshold of 75%.
Results
With two rounds completed, consensus for recommendation was reached for 2 prevention interventions in both low- and high-risk settings and near-consensus for recommendation was reached for 1 prevention intervention in the high-risk setting. With regards to the management of acute radiation dermatitis, there was consensus for recommendation for 1 product. However, a significant number of interventions did not receive recommendations for either prevention or management due to insufficient or conflicting evidence. Two subsequent rounds are currently being held, and final recommendations are planned for the spring 2024.
Conclusions
This pan-Canadian modified Delphi consensus initiative provides expert-reviewed and evidence-based recommendations for interventions to prevent and manage acute radiation dermatitis in breast cancer patients, highlighting areas where consensus among experts has been achieved, with the goal of standardising care and minimizing unnecessary costs.
Legal entity responsible for the study
The authors.
Funding
L'Oreal Canada.
Disclosure
T. Hijal: Financial Interests, Personal, Advisory Board: L'Oreal Canada. E. Wiebe: Financial Interests, Personal, Sponsor/Funding, Travel reimbursement: L'Oreal Canada; Financial Interests, Personal, Invited Speaker: Seagen. J. Bourque: Financial Interests, Personal, Advisory Board: Pfizer, Elekta. V. Theberge: Financial Interests, Personal, Sponsor/Funding, Travel reimbursement: L'Oreal Canada. E. Chow: Non-Financial Interests, Personal, Member: MASCC Onco-dermatology study group; Non-Financial Interests, Personal, Product Samples, For pilot study: StrataXRT; Non-Financial Interests, Personal, Product Samples, For phase III trial: Mepitel Film. M. Sauder: Financial Interests, Personal, Stocks/Shares: Merck, Johnson & Johnson; Financial Interests, Personal, Advisory Role: L'Oreal. N. Dayeh: Financial Interests, Personal, Full or part-time Employment: L'Oreal Canada. All other authors have declared no conflicts of interest.